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Abstract
Background: Acylation stimulating protein (ASP) is an adipogenic hormone that stimulates triglyceride (TG) synthesis 
and glucose transport in adipocytes. Previous studies have shown that ASP-deficient C3 knockout mice are 
hyperphagic yet lean, as they display increased oxygen consumption and fatty acid oxidation compared to wildtype 
mice. In the present study, antibodies against ASP (Anti-ASP) and human recombinant ASP (rASP) were tested in vitro 
and in vivo. Continuous administration for 4 weeks via osmotic mini-pump of Anti-ASP or rASP was evaluated in 
wildtype mice on a high-fat diet (HFD) to examine their effects on body weight, food intake and energy expenditure.
Results: In mature murine adipocytes, rASP significantly stimulated fatty acid uptake (+243% vs PBS, P < 0.05) while 
Anti-ASP neutralized the rASP response. Mice treated with Anti-ASP showed elevated energy expenditure (P < 0.0001), 
increased skeletal muscle glucose oxidation (+141%, P < 0.001), reduced liver glycogen (-34%, P < 0.05) and glucose-6-
phosphate content (-64%, P = 0.08) compared to control mice. There was no change in body weight, food intake, 
fasting insulin, adiponectin, CRP or TG levels compared to controls. Interestingly, HFD mice treated with rASP showed 
the opposite phenotype with reduced energy expenditure (P < 0.0001) and increased body weight (P < 0.05), 
cumulative food intake (P < 0.0001) and liver glycogen content (+59%, P < 0.05). Again, there was no change in 
circulating insulin, adiponectin, CRP or TG levels, however, plasma free fatty acids were reduced (-48%, P < 0.05).
Conclusion: In vitro, Anti-ASP effectively neutralized ASP stimulated fatty acid uptake. In vivo, Anti-ASP treatment 
increased whole body energy utilization while rASP increased energy storage. Therefore, ASP is a potent anabolic 
hormone that may also be a mediator of energy expenditure.
Background
Acylation stimulating protein (ASP) is a circulating adi-
pokine elevated in obesity, diabetes and cardiovascular
disease [1] as well as other metabolic disorders with
hyperlipidemia such as polycystic ovarian syndrome
(PCOS) [2], hypothyroidism [3] and lipoprotein lipase
(LPL) deficiency [4]. ASP influences fat storage by stimu-
lating diacylglycerol acyltransferase (DGAT) activity, the
rate limiting step in triglyceride (TG) synthesis [5],
increasing glucose transporter GLUT4 translocation [6],
indirectly stimulating LPL activity in adipose tissue [7],
and inhibiting lipolysis [8]. These effects are mediated
through the C5L2 receptor, a G protein-coupled receptor
highly expressed in adipose tissue depots, skeletal muscle
and liver [9,10].
ASP (C3adesArg) is the cleavage product of comple-
ment C3 (reviewed in [1]); accordingly C3 knockout
(C3KO) mice are ASP-deficient. Furthermore, C3KO
mice are characterized by having increased food intake
[11,12], delayed postprandial dietary triglyceride clear-
ance [13,14], increased oxygen consumption [12,15], and
greater muscle fatty acid oxidation relative to glycolysis
[12]. ASP receptor KO mice, C5L2KO, share a similar
phenotype with C3KO mice. Overall fatty acid oxidation
is augmented (reduced respiratory quotient), food intake
is increased, and they also display delayed postprandial
lipid clearance [16]. It is interesting to note that mice
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lacking either ASP or C5L2 from in utero have less TG
storage capacity in adipose tissue and greater fatty acid
oxidation in muscle. Moreover, these effects have also
b e e n  o b s e r v e d  i n  w i l d t y p e  ( WT )  m i c e  t r e a t e d  a c u t e l y
with ASP/C5L2-neutralizing antibodies [17].
In a previous short-term pilot study, antibodies
designed to block ASP-C5L2 interaction, i.e., antibodies
against ASP (Anti-ASP) or C5L2 (Anti-C5L2), were both
shown to inhibit ASP stimulated TG synthesis and glu-
cose transport in preadipocytes and mature adipocytes
[17]. These antibodies were then administered daily to
WT mice on a low-fat diet over the course of a short 10
day study. The results showed no difference in body
weight or food intake with antibody treatment, however
there were significant changes in lipid metabolism and
adipose tissue and skeletal muscle enzyme activity. Adi-
pose tissue TG mass and LPL activity were reduced, while
skeletal muscle AMPK activity was increased [17]. There-
fore, even with short term administration, neutralizing
antibodies blocking ASP-C5L2 interaction resulted in
beneficial altered lipid distribution and energy utilization
in WT mice.
Based on the previous observations of altered muscle
activity and substrate utilization, the present study exam-
ines energy expenditure and substrate storage over a lon-
ger timeframe (4 weeks) in WT mice administered a
c o n s t a n t  d e l i v e r y  o f  a n t i b o d y .  F u r t h e r ,  t h e  m i c e  w e r e
challenged with a high-fat diet two weeks prior to, and
during, the treatment. In addition, in the present study,
we investigated the consequences of ASP supplementa-
tion in WT mice following initiation of a high-fat diet.
Methods
Anti-ASP and recombinant ASP production
Polyclonal rabbit antibody against human ASP (Anti-
ASP) was developed as previously described [18]. The
IgG fraction was isolated from plasma by gamma sephar-
ose chromatography (GE Healthcare, Chicago, IL, USA)
and the polyclonal antibody cross-reacted with mouse
ASP [17]. Non-immune IgG (NI-IgG) was purchased
from Sigma (Sigma, St Louis, MO, USA). For the produc-
tion of recombinant ASP (rASP), the portion of the
human C3 gene representing ASP (C3adesArg) was
cloned into the NcoI/EcoRI restriction sites of pET32a(+)
(Novagen, Madison, WI, USA). An extra alanine (GCC)
codon was incorporated to be able to use NcoI as a clon-
ing site. The vector was digested with NdeI to excise out
the thioredoxin tag (TRX.tag) and religated to obtain
pET_his_ASP vector containing the His-tagged ASP
sequence. The cell line used to produce recombinant ASP
was Origami B (DE3) (Novagen), a BL21 derived cell line
lacking thioredoxin and glutathione reductase genes. Fro-
zen OriB-pET-his-ASP scrapes were inoculated and
grown overnight at 37°C with shaking (220 rpm) in bacte-
rial media (25 g/L LB Broth, EMD Biosciences, Madison,
WI, USA) supplemented with 10 ug/mL kanamycin
(Invitrogen, Burlington, ON, Canada) and 100 ug/mL
carbenicillin (Invitrogen). Cultures were diluted (1.5 mL/
L) in bacterial media, incubated 5-8 hours (37°C, 220
rpm) until an OD600 of 0.6-0.8 was reached, then supple-
mented with IPTG (Isopropyl ß-D-1-thiogalactopyrano-
side, QIAGEN, Mississauga, ON, Canada, 1 mM final
concentration) and incubated overnight (25°C, 220 rpm).
Cell pellets were collected (centrifugation 3000 ×g, 20
min), lysed with 10 mL Bugbuster (EMD Biosciences), 10
mg lysozyme (Sigma) and 10 μL benzonase nuclease (20
U/mL, EMD Biosciences), vortexed well, shaken 30 min
at RT, centrifuged (3000 g, 5 min, 4°C) and the superna-
tant decanted. The lysis step was repeated with an addi-
tional 10 mL, then 5 mL. All supernatants were pooled,
acidifed with 10N HCl (final 1 N HCl), stirred (15 min
RT), centrifuged (3000 g, 20 min, 4°C), pooled, adjusted
to pH 7.4 with 10 N NaOH and centrifuged (3000 g, 20
min, 4°C). rHis-ASP was purified with binding to Ni2+-
Sepharose column (GE Healthcare). Following loading of
rHis-ASP, the column was washed with buffer (50 mM
NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 74.) and
eluted with acidified buffer (0.625 N HCl in buffer, pH
~2.0). For removal of rHis-tag, rHis-ASP solution was
carefully adjusted to pH 8.0, enterokinase (New England
Biolabs, Pickering, ON, Canada) was added (0.063 ug/20
mL), and incubated overnight at RT (18°C) with gentle
shaking. rASP was purified by HPLC as previously
described [19].
In vitro fatty acid uptake
3T3-L1 preadipocytes cells were obtained from ATCC
(Manassas, VA, USA). Cells were routinely grown in Dul-
becco's modified Eagle's medium (DMEM) + 10% (v/v)
fetal calf serum (Invitrogen) at 37°C, 5% CO2. 3T3-L1
preadipocytes were differentiated into mature adipocytes
as described previously [7]. Differentiated adipocytes in
48 well plates were preincubated (37°C, 5% CO2) in serum
free medium for 1 hour then incubated with PBS (base-
line synthesis), insulin (100 nM) (Sigma), rASP (100 nM),
or rASP (100 nM) + Anti-ASP (0.2, 0.3, 0.4 μ g/mL, added
before the addition of ASP) for 1 hour. Uptake of fluores-
cently labeled fatty acids was measured over time in adi-
pocytes as described [20,21] using a QBT™ fatty acid
uptake assay kit (Molecular Devices, Sunnyvale, CA,
U S A )  a s  o u t l i n e d  b y  t h e  m a n u f a c t u r e r .  F o l l o w i n g  t h e
addition of BODIPY-fatty acid, fatty acid uptake is mea-
sured in real-time over 120 min in a bottom-reading fluo-
rescent microplate reader.
Mice
Male C57BL/6 mice (aged 7-8 weeks) were purchased
from Charles River Laboratories (Wilmington, PA, USA).Paglialunga et al. BMC Physiology 2010, 10:4
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The mice were maintained on a high-fat diet (45% kcal
from fat, Research Diet, New Brunswick, NJ, USA)
throughout the study (total of 6 weeks) and housed indi-
vidually in a sterile barrier facility with a 12 h light: 12 h
dark cycle. Two weeks following the start of the high-fat
diet regimen, the mice were surgically implanted with an
osmotic mini-pump (model 2004) (Durect Corp., Cuper-
tino, CA, USA). Briefly, the mice were first sedated with
ketopiofen (5 mg/kg) then anesthetized with isofluorane.
Under sterile conditions, a small incision was made
between the skin and scapulae and the osmotic pump was
inserted subcutaneously into the mouse. The incision was
then closed with sutures according to manufacturer's
instructions. All protocols were conducted in accordance
with the CACC guidelines and approved by the Univer-
sity Animal Care Committee. The mice were divided into
four groups where they were continuously delivered; i)
non-immune IgG n = 6 (2 μg/μL); ii) Anti-ASP n = 7 (4
μg/μL); iii) PBS (vehicle) n = 6; or iv) recombinant ASP
(95 pmol/μL) in PBS n = 5 for 4 weeks at a flow rate of
0.25 μL/hr. Twenty-eight days following mini-pump
i n s e r t i o n  ( 6  w e e k s  o n  h i g h - f a t  d i e t ) ,  m i c e  w e r e  f a s t e d
overnight, euthanized, and tissues, blood samples and the
mini-osmotic pumps were collected. Average pump rate
was calculated as the difference between the initial vol-
ume loaded and the residual volume divided by 28 days.
Plasma Measurements
Overnight fasting plasma samples were taken 9 days after
the surgery by submandibular bleed and during sacrifice
by cardiac puncture (day 28). Plasma human rASP levels
were measured by an in-house ELISA which does not
cross-react with mouse ASP, background non-specific
(PBS) values were subtracted [18]. Rabbit IgG was mea-
sured by Easy-titer IgG assay kit (Thermo Fisher Scien-
tific Inc., Rockford, IL, USA), to track the efficacy of
pump delivery. Plasma TG (Roche Diagnostics, Indianap-
olis, IN, USA), non-esterified fatty acids (NEFA) (Wako
Chemicals, Richmond, VA, USA) and glucose (Sigma)
were measured using colorimetric enzymatic kits. Insulin
and adiponectin were measured using RIA kits (Linco,
St.Charles, MO, USA); interleukin-6 (IL-6) (BD, Franklin
Lakes, NJ, USA) and CRP (Immunology, Consultants
Laboratory, Inc., Newberg, OR, USA) were measured by
ELISA. C3 was measured by immunoturbidimetric assay
(Kamiya Biomedical Company, Seattle, WA, USA).
Body Weight, Food Intake and Indirect Calorimetry
Body weight and food intake were measured 3 times a
week. Food intake results are reported as cumulative food
intake in kcal. Food efficiency was calculated as the food
intake in kcal over body weight gain in grams. Calorime-
try measurements were taken 15-17 days after the sur-
gery. Oxygen consumption (VO2) and carbon dioxide
production (VCO2) were measured over a 24 hour period
in an open circuit system after 48 hours equilibration as
previously described [22]. VO2 and VCO2 were calculated
as mL/kg/min and RQ (respiratory quotient) was taken as
the quotient of VCO2/VO2. Energy expenditure (kcal/kg/
min) was calculated as 3.91VO2+1.1VCO2[23].
Skeletal muscle ex vivo assays
Quadriceps muscles were excised and placed into room
temperature Krebs-Ringer Buffer (KRB) containing 1%
fatty acid free BSA and 5 mM glucose. For fatty acid oxi-
dation, the muscle was cut into small pieces then incu-
bated with 1 mM palmitic acid [3H palmitate, 5 μCi/μL]
(Perkin-Elmer Life Sciences, Boston, MA, USA) in KRB
for 2 hours. Oxidation was measured as the production of
3H2O into the aqueous phase following a Folch extraction
as previously described [16]. The organic extract was
dried down in a speedvac, resuspended in 100 μL chloro-
form/methanol (2:1) and lipids were separated using sil-
ica thin layer chromatography plates. The extracted lipids
were separated using heptane/isopropyl ether/acetic acid
(60:40:4) as the separation solvent for 45 min. The plate
was developed in iodine vapour and diglyceride and trig-
lyceride bands were identified and scraped into scintilla-
tion vials for counting. Following overnight solubilization
of the tissue remnants in NaOH, total proteins were mea-
sured by Bradford assay (BioRad, Hercules, CA, USA).
Glucose oxidation was performed as previously described
[12].
Substrate content and enzyme activity assays
Liver glycogen was degraded into glycosyl units by incu-
bating small liver pieces (~50 mg) in 1 M HCl at 100°C for
3 hours [24]. The extracts were neutralized with TRIS-
KOH and the supernatant was assayed for glucose using a
commercial colorimetric kit (Sigma). Results are
expressed as μmoles/g glycosyl units per liver weight. For
glucose-6-phosphate measurements, small liver pieces
(~25 mg) were homogenized in 6% perchloric acid. The
supernatant was clarified by centrifugation and neutral-
ized with KOH in the presence of phenol red. The result-
ing potassium perchlorate precipitate was removed by
centrifugation and the supernatant was enzymatically
assayed for glucose 6-phosphate by following NADPH
accumulation at 340 nm in presence of glucose 6-phos-
phate dehydrogenase. Results are expressed as nmoles/g
liver sample. Neutral lipids were extracted from muscle
and liver samples (30-50 mg) in a heptane/isopropanol
(3:2) solution overnight at 4°C. The next day organic
extracts were assessed for TG content using a commercial
colorimetric kit (Roche Diagnostics) and total proteinPaglialunga et al. BMC Physiology 2010, 10:4
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content was measured as described above. Results are
expressed as μmoles of TG per gram of protein. Glucoki-
nase (GK) enzyme activity was measured as previously
described [12] however; solution volumes were modified
for a 96-well plate and ODs were measured on a plate
reader (BioTek Instruments, Inc. Winooski, VT, USA).
Statistics
Results are expressed as means ± SEM. Results were ana-
lyzed by two-way ANOVA (two variables), one-way
ANOVA followed by Dunnett's post-hoc test (one vari-
able, more than two groups) or two-tail t-test (two
groups). For indirect calorimetry measurements body
weight and food intake, Group and Time P values are
indicated in the graphs. Average area-under the curve
(AUC) was calculated for light (12 hours) and dark (12
hour) energy expenditure. Significance was set as P value
< 0.05, where NS represents non-significant values. All
graphs and statistical analyses were performed using
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA,
USA).
Results
Anti-ASP blocks in vitro ASP-stimulated fatty acid uptake
Recombinant ASP (rASP) activation and antibody neu-
tralization were first tested in an in vitro system. Insulin
(positive control, a known lipogenic hormone) and rASP
significantly stimulated fatty acid uptake in murine adi-
pocytes to a similar degree (Figure 1A), with maximal
stimulation of 285 ± 49% (P < 0.01) for insulin and 243% ±
24% (P < 0.05) for rASP, vs PBS set at 100%. This is also
presented as a 2.7-fold (P < 0.01) increase for insulin and
2.4-fold (P < 0.01) increase for rASP in the incremental
area-under-the-curve (Figure 1B). The addition of
increasing concentrations of Anti-ASP significantly
reduced rASP stimulated fatty acid uptake to basal levels
(maximal stimulation: 98% ± 4%, 120% ± 10%, and 144% ±
18%, vs PBS set at 100% for 0.2, 0.3 and 0.4 μg/mL Anti-
ASP respectively, not significantly different from PBS)
(Figure 1A and 1B).
Monitoring exogenous antibody levels and plasma 
hormones
Mice were treated by osmotic mini-pump for 4 weeks
with neutralizing Anti-ASP or control non-immune IgG
(NI-IgG). Plasma samples were taken 9 days after implan-
tation of the osmotic pump and at the end of the study to
track the amount of antibody delivered into circulation.
Figure 2A shows that on day 9 rabbit NI-IgG and Anti-
ASP antibodies were detected (~4% of starting material).
However, by the end, the levels of both NI-IgG and Anti-
ASP were greatly reduced (~0.1% of starting material).
Since there was no difference in osmotic mini-pump rate
for PBS, rabbit antibodies or rASP treatments (data not
shown), reduced antibody levels may be attributed to
enhanced antibody clearance. Anti-ASP blocking anti-
body treatment had no effect on mouse body weight (NI-
IgG: 29.2 ± 0.4 g and Anti-ASP: 29.6 ± 0.3 g, NS, n = 6-7),
average food intake (NI-IgG: 13.8 ± 0.5 kcal/day and
Anti-ASP: 14.3 ± 0.5 kcal/day, NS, n = 6-7) or food effi-
ciency (NI-IgG: 200.1 ± 21.2 kcal/g and Anti-ASP: 165.6
± 25.8 kcal/g, NS, n = 6-7), consistent with our previous
report during a 10 day study [17]. There was also no dif-
ference in adipose tissue depots, liver or spleen weight
between the two groups (data not shown). IL-6 levels
were slightly but significantly elevated in Anti-ASP mice
(P < 0.05, Figure 2B). However, CRP levels, a marker of
inflammation, were normal (Figure 2C). Anti-ASP did
Figure 1 In vitro fatty acid uptake. (A) Fluorescent BODIPY fatty acid uptake in real-time analysis over 120 mins. Differentiated adipocytes were treat-
ed with PBS (solid black line), insulin (solid grey line, 100 nM), rASP (hatched black line, 100 nM) or rASP (100 nM) + Anti-ASP, at the following concen-
trations from bottom to top: 0.2, 0.3 and 0.4 μg/mL, for n = 3. (B) Incremental area-under-the-curve (AUC) analysis of PBS (white solid bar) insulin (black 
solid bar, 100 nM), rASP (white hatched bar, 100 nM) and rASP (100 nM) + Anti-ASP (gray solid bars, concentrations as indicated) for n = 3. All values 
are presented as mean ± SEM, where ** P < 0.01.
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not have an effect on fasting glucose levels after nine days
of treatment (NI-IgG: 6.22 ± 0.62 mmol/L and Anti-ASP:
6.58 ± 0.54 mmol/L, NS, n = 6-7). Furthermore, there was
no difference in plasma adiponectin, insulin, C3, or lipid
levels between the two groups at the end of the study
(Table 1).
Anti-ASP treatment results in increased energy 
expenditure and glucose oxidation
Twenty-four hour energy expenditure was significantly
elevated in Anti-ASP treated mice (P < 0.0001, Figure
2D). Analysis of dark and light 12-h cycles separately
indicates a significant increase with anti-ASP for both
Table 1: NI-IgG and Anti-ASP Treated Mice Hormone and Lipids Levels
Plasma NI-IgG (n = 5) Anti-ASP (n = 6)
Adiponectin (ug/mL) 7.67 ± 0.51 8.85 ± 0.71
Insulin (ng/mL) 0.30 ± 0.07 0.28 ± 0.03
C3 (mg/mL) 0.41 ± 0.02 0.37 ± 0.03
Triglycerides (mmol/L) 0.65 ± 0.02 0.56 ± 0.08
NEFA (mmol/L) 0.99 ± 0.22 0.57 ± 0.05
Values are presented as mean ± SEM. No statistically significant difference was identified as determined by unpaired two-tail t-test.
Figure 2 Plasma antibody, IL-6, CRP and indirect calorimetry results for mice treated with ASP-neutralizing antibody or control antibody. 
Fasting plasma samples from NI-IgG treated mice (n = 6, white bars) and Anti-ASP treated mice (n = 7, black bars). (A) Polyclonal rabbit antibody de-
tected in mouse plasma following 9 days and 4 weeks treatment. (B) Plasma IL-6 and (C) CRP levels at end of treatment. Results were analyzed by 
unpaired two-tailed t-test. (D) Energy expenditure measured over 24 hours for NI-IgG treated mice (n = 6, white squares) and Anti-ASP treated mice 
(n = 7, black squares). Results were analyzed by two-way ANOVA. Group and time P values are reported in graph, their interaction was not significant. 
Analysis of light and dark periods separately (2-way ANOVA) indicated a significant difference between Anti-ASP and NI-IgG for both time periods (P 
< 0.0001) (E) Light and dark phase energy expenditure calculated as the area-under the curve (AUC). (F) respiratory quotient (RQ) measured over 24 
hours for NI-IgG treated mice (white squares) and Anti-ASP treated mice (black squares). Results were analyzed by two-way ANOVA. Group and time 
P values are reported in graph, their interaction was not significant. All values are presented as mean ± SEM, where * P < 0.05.
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time periods (P < 0.0001, 2-way ANOVA, AUC Figure
2E). While RQ increased with feeding (indicating
increased glucose utilization during this period), there
w a s  n o  c h a n g e  i n  R Q  i n  e i t h e r  d a r k  o r  l i g h t  c y c l e s
between the two groups, suggesting a whole body
increase in both glucose and fatty acid oxidation (Figure
2F). To investigate the mechanism of augmented whole
body energy expenditure, we evaluated glucose and fatty
acid consumption in skeletal muscle and liver. In the skel-
etal muscle, glucose oxidation was significantly increased
more than two-fold in Anti-ASP treated mice (P < 0.01,
Figure 3A). On the other hand, palmitate oxidation was
reduced (P < 0.05, Figure 3B) with a shift of palmitate
from oxidation towards incorporation into diglycerides
(P = 0.05, Figure 3C) with no change in TG incorporation
or total TG mass (data not shown). In the liver, glycogen
content was decreased by 34% (P < 0.05, Figure 3D) asso-
ciated with a trend in reduced glucose-6-phosphate con-
tent (P = 0.08, Figure 3E) and no change in glucokinase
(GK) activity (NS, Figure 3F). Also, there was no differ-
ence in liver TG mass (NI-IgG: 40.6 ± 4.6 μmoles/g and
Anti-ASP: 43.0 ± 5.3 μmoles/g, NS, n = 5-7).
NEFA levels were reduced with recombinant ASP treatment
Next, we treated WT mice with human rASP for 4 weeks
to enhance ASP action. Immunoreactive circulating
human rASP was detected at ~0.3 pmol/mL on day 9 and
remained constant until the end of the study period (Fig-
ure 4A). Interestingly, NEFA levels were significantly
lower in the rASP treated mice (P < 0.05, Figure 3B). Fast-
ing glucose levels were similar between rASP and PBS
treated mice (PBS: 6.77 ± 0.74 and rASP: 6.81 ± 0.58
mmol/L, NS, n = 5-6). In addition, no difference in
plasma TG, insulin or adiponectin were detected
between PBS and rASP treated mice, however C3 levels
were significantly elevated in the rASP treated mice
(Table 2).
rASP treatment increases body weight and food intake in 
WT mice
Monitoring of body weight during the treatment period
indicated a significant increase in the rASP treated group
within the middle time period of treatment (days 9-24,
Figure 4C, P < 0.0043). However, at the end, a similar final
fasting body weight was measured (PBS: 30.0 ± 0.6 g and
rASP: 30.3 ± 0.8 g, NS, n = 5-6). This increase in body
weight was associated with a small but significant
increase in cumulative food intake (P < 0.0001, Figure
4D). Food efficiency, calculated as food intake relative to
body weight, was comparable between the groups (PBS:
127.5 ± 18.8 kcal/g and rASP: 151.0 ± 41.2 kcal/g, NS).
During this time period, energy expenditure was signifi-
cantly reduced in rASP treated mice (P < 0.0001, Figure
5A), in both the light and dark cycles (Figure 5B). While
respiratory quotient changes with feeding, there was no
difference between the groups (Figure 5C). Analyses of ex
Figure 3 Markers of skeletal muscle and liver energy expenditure and glucose storage. Ex vivo quadriceps muscle (A) glucose oxidation, (B) 
fatty acid oxidation and (C) fatty acid incorporation into diglyceride. Ex vivo liver (D) glycogen content, (E) glucose-6-phosphate content and (F) glu-
cokinase activity. All values are presented as mean ± SEM for NI-IgG treated mice (n = 6, white bars) and Anti-ASP treated mice (n = 7, black bars), 
where* P < 0.05 and ** P < 0.01 analyzed by unpaired two-tailed t-test.
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vivo skeletal muscle oxidation revealed no change in glu-
cose or palmitate oxidation for rASP and control mice
(Table 2). Meanwhile, liver glycogen content was signifi-
cantly increased by 59% in rASP treated mice (P < 0.05)
w i t h  n o  c h a n g e  i n  g l u c o s e - 6 - p h o p h a t e  o r  T G  c o n t e n t
(Table 2).
Discussion
The present study examines the effects of constant deliv-
ery of an ASP-neutralizing antibody or rASP in high-fat
diet fed mice. Significant increases in energy expenditure
and glucose oxidation coupled to reduced glycogen con-
tent were observed in Anti-ASP treated mice. In accor-
dance with the Randle cycle [25], muscle fatty acid
oxidation was suppressed while the glycolytic machinery
was upregulated. On the other hand, rASP treated mice
displayed reduced energy expenditure with increases in
body weight (transient), and increased food intake and
liver glycogen content. Therefore, Anti-ASP treatment
increased whole body energy expenditure and glucose
utilization in the muscle and decreased glucose storage in
the liver while rASP treatment showed the opposing
effects of decreased energy expenditure and increased
liver glycogen.
Some of the limitations of the study include the small
sample number and the reduced antibody levels detected
towards the end of the study. While in cultured mouse
adipocytes, low Anti-ASP antibody levels were sufficient
to neutralize ASP-stimulated fatty acid uptake, the lack of
body weight change between Anti-ASP and NI-IgG
treated mice at study end could potentially be explained
by reduced neutralization capacity due to the low circu-
lating antibody levels detected. Therefore, in future stud-
ies, a longer lasting ASP blocking function, such as might
be obtained with FAb fragments or antagonists, would be
the ideal intervention tool.
Table 2: PBS and rASP Treated Mice Plasma, Muscle and Liver Analysis
Plasma PBS (n = 6) rASP (n = 5)
Adiponectin (ug/mL) 8.48 ± 0.42 8.00 ± 0.51
Insulin (ng/mL) 0.34 ± 0.06 0.31 ± 0.08
IL-6 (pg/mL) 24.72 ± 0.88 23.65 ± 1.18
CRP (pg/mL) 1.51 ± 0.38 1.00 ± 0.16
C3 (mg/mL) 0.36 ± 0.02 0.48 ± 0.03*
Triglycerides (mmol/L) 0.99 ± 0.24 0.63 ± 0.04
Muscle
Glucose Oxidation (% PBS) 100.0 ± 11.3 73.5 ± 12.6
Palmitate Oxidation (%PBS) 100.0 ± 8.8 96.4 ± 10.2
Liver
Glycogen content (umoles/g) 142.3 ± 18.9 226.9 ± 31.2*
G6P content (nmoles/g) 221.6 ± 82.0 342.8 ± 57.1
Triglyceride mass (umoles/g) 34.2 ± 2.0 32.8 ± 3.0
GK activity (umoles/g/min) 0.69 ± 0.06 0.72 ± 0.07
Values are presented as mean ± SEM where * P < 0.05 as determined by unpaired two-tail t-test.Paglialunga et al. BMC Physiology 2010, 10:4
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Figure 4 Effects of recombinant ASP treatment on plasma NEFA levels, body weight and food intake in wildtype mice. Fasting plasma sam-
ples from PBS treated mice (n = 6, white hatched bars) and rASP treated mice (n = 5, gray hatched bars). (A) Human rASP detected in mouse plasma 
following 9 days and 4 weeks treatment. (B) Fasting NEFA levels after 4 weeks treatment. Results were analyzed by unpaired two-tailed t-test. (C) Body 
weight (g) and (D) cumulative food intake (kcal) for PBS (n = 6, white circles) and rASP (n = 5, black circles) treated mice. Results were analyzed by two-
way ANOVA. Group and Time P values are reported in graph. All values are presented as mean ± SEM, where * P < 0.05.
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Elevated fasting plasma ASP levels are often present in
obesity and associated diseases and correlate with BMI as
well as percent body fat (reviewed in [1]). Previous
reports have shown that ASP stimulates fatty acid trap-
ping in white adipose tissue [26] and adipocytes [7], stim-
ulating fatty acid uptake and esterification in both
preadipocytes and mature adipocytes [5,27]. In the pres-
ent study, rASP treatment reduced fasting plasma NEFA
levels, suggesting increased fatty acid uptake and storage.
Further we showed that exogenous rASP stimulated
weight gain and food intake while decreasing energy
expenditure in mice. Consistent with these in vivo and in
vitro effects, we hypothesize that ASP may play a role in
increased weight gain.
In our previous pilot study, we demonstrated that Anti-
ASP significantly increased muscle and liver AMPK
activity as well as reducing muscle LPL activity [17].
While this was a short-term (10 days) daily injection
study in low-fat diet fed mice, this study provided strong
support for ongoing evaluation, and is consistent with
our present study. In both the 10 day and 4 week studies,
there was no change in food intake compared to control
WT mice. In addition, Anti-ASP treatment in the two
studies had no effect on metabolic hormones such as
insulin or adiponectin levels. Further, our previous pilot
study suggested an increase in energy expenditure via an
increase in AMPK activity, a well known marker of a cell's
"fuel gauge", indicating ATP/AMP availability [28].  We
directly demonstrate that in our present study of Anti-
ASP treated mice. Finally, Anti-ASP treatment does not
promote liver lipotoxicity, as both studies showed no
change in liver TG accumulation compared to controls.
As mentioned above, a significant outcome of blocking
ASP in WT mice was increased whole body energy
expenditure, evaluated by indirect calorimetery. Interest-
ingly, C3KO mice on either a low-fat diet [15] or a high-
fat diet [12] also displayed increased oxygen consump-
tion, suggesting a role for ASP in energy metabolism.
However while C3KO mice demonstrated a decrease in
RQ (suggesting a preferential increase in fat oxidation), in
the present Anti-ASP study, there was no change in RQ,
suggesting a comparable increase in both fat and glucose
oxidation. One major site of energy utilization is muscle.
On a high fat diet, C3KO mice demonstrated greater fatty
acid oxidation vs WT mice [12], while Anti-ASP mice
demonstrate increased glucose oxidation vs WT mice in
skeletal muscle. There are several factors that could
explain this difference including length of time on a high-
fat diet (12 weeks for C3KO mice, 6 weeks in the present
study) or in utero compensatory mechanisms in C3KO
mice. Either way, energy expenditure is increased. An
additional point of difference between C3KO and Anti-
AS P trea t ed mic e is t heir food in tak e. C3K O mice are
hyperphagic [11,12], while there was no change in food
intake in the present study. Again, differences could be
related to time of treatment (4 weeks antibody injection
vs in utero changes). Possibly, C3KO hyperphagia is cen-
trally regulated as C5L2 (ASP receptor) has been identi-
fied in the brain [29]. We speculate that peripherally
administered Anti-ASP treatment had no effect on food
intake, because of a lack of central targeting, since anti-
bodies cannot cross the blood brain barrier, although this
remains to be evaluated. In summary, ASP neutralization
effectively augmented energy expenditure without nega-
tively affecting food intake.
It is interesting to note that the physiological results
observed with either treatment are independent of
changes in adiponectin, insulin and CRP levels, however
Anti-ASP treated mice did display slightly increased
plasma IL-6. IL-6 is a pro-inflammatory cytokine shown
to influence glucose metabolism, however, its effects on
insulin sensitivity remain controversial [30,31]. Wernst-
edt et al. showed that IL-6 KO mice had increased plasma
ASP levels prior to the development of their mature onset
obesity, and IL-6 injection rapidly reduced circulating
ASP levels [32]. There appears to be a reciprocal relation-
ship between IL-6 and ASP levels although the exact
nature of this regulation is unknown and warrants further
investigation.
Conclusion
In summary, enhancing ASP action with the addition of
recombinant ASP resulted in increased body weight and
food intake, supporting a direct role of increased ASP in
promoting obesity. Furthermore, targeting ASP
decreased adipose tissue TG mass and LPL activity in our
previous study [17] and increased energy expenditure,
oxygen consumption and muscle glucose oxidation in the
present study. Overall, Anti-ASP increased whole body
energy utilization while rASP increases energy storage.
Therefore, ASP may be a mediator of energy regulation.
However, a direct role for ASP in tissues that express its
receptor C5L2, such as muscle, liver and central nervous
system [29], remains to be determined.
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